Mucopolysaccharidosis type VI phenotypes-genotypes and antibody response to galsulfase by Brands, M.M.M.G. (Marion) et al.
Brands et al. Orphanet Journal of Rare Diseases 2013, 8:51
http://www.ojrd.com/content/8/1/51RESEARCH Open AccessMucopolysaccharidosis type VI
phenotypes-genotypes and antibody response
to galsulfase
Marion M Brands1, Marianne Hoogeveen-Westerveld1, Marian A Kroos1, Willemieke Nobel1, George J Ruijter1,3,
Lale Özkan1, Iris Plug1, Daniel Grinberg2, Lluïsa Vilageliu2, Dicky J Halley1, Ans T van der Ploeg1
and Arnold J Reuser1,3*Abstract
Background: Mucopolysaccharidosis type VI (Maroteaux-Lamy syndrome; MPS VI) is an autosomal recessive lysosomal
storage disorder in which deficiency of N-acetylgalactosamine 4-sulfatase (arylsulfatase B; ARSB) leads to the storage of
glycosaminoglycans (GAGs) in connective tissue. The genotype-phenotype correlation has been addressed in several
publications but the picture is not complete. Since 2007, enzyme-replacement therapy (ERT) has been available for
patients with MPS VI in the Netherlands. The purpose of our study was to learn more about the genotype-phenotype
correlations in MPS VI and the antibody response to ERT with galsulfase (recombinant human arylsulfatase B).
Methods: We identified ARSB mutations in 12 patients and used site-directed mutagenesis to study their effect.
Antibody levels to galsulfase were measured using ELISA and a semi-quantitative immunoprecipitation method. We
assessed the in vitro inhibitory effect of antibodies on galsulfase uptake and their effect on clinical outcome.
Results: Five patients had a rapidly progressive phenotype and seven a slowly progressive phenotype. In total 9
pathogenic mutations were identified including 4 novel mutations (N301K, V332G, A237D, and c.1142 + 2 T > C) together
composing 8 pathogenic genotypes. Most mutations appeared not to affect the synthesis of ARSB (66 kD precursor), but
to hamper its maturation (43 kD ARSB). Disease severity was correlated with urinary GAG excretion. All patients
developed antibodies to galsulfase within 26 weeks of treatment. It was demonstrated that these antibodies can inhibit
the uptake of galsulfase in vitro.
Conclusions: The clinical phenotypes and the observed defects in the biosynthesis of ARSB show that some of the
mutations that we identified are clearly more severe than others. Patients receiving galsulfase as enzyme-replacement
therapy can develop antibodies towards the therapeutic protein. Though most titers are modest, they can exceed a level
at which they potentially affect the clinical outcome of enzyme-replacement therapy.
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Mucopolysaccharidosis type VI (Maroteaux-Lamy syn-
drome; MPS VI; MIM 253200) is a lysosomal storage dis-
order in which the deficiency of N-acetylgalactosamine
4-sulfatase leads to the storage of glycosaminoglycans
(GAGs) in connective tissue. It is an autosomal reces-
sive disease caused by mutations in the ARSB
(arylsulfatase B) gene, which is located on chromosome
5q13-q14. More than 130 mutations have been identi-
fied, the vast majority being missense mutations [1]. Al-
though the genotype-phenotype correlation has been
described for several mutations, it is far from complete
[2]. Patients with MPS VI present with connective-tissue
pathology of varying severities; the main symptoms in-
clude restrictive pulmonary disease, cardiomyopathy,
hepatosplenomegaly, corneal clouding, and bone disease
with short stature. The variability in disease covers a
clinical spectrum which is common in lysosomal stor-
age disorder [1]. Since 2007, enzyme replacement ther-
apy (ERT) has been available for patients with MPS VI
in the Netherlands, where treatment and standardized
care are concentrated at the national expertise centre
at Erasmus MC University Medical Center. The ef-
fects of ERT on endurance, pulmonary function,
hepatosplenomegaly, and GAG excretion were de-
scribed in previous publications [3-5]. Antibody for-
mation is common in patients receiving ERT for
lysosomal storage disorders [6]. In Fabry disease and
Pompe disease, for instance, it is a well-documented
problem [7,8]. Due to the patient’s enzyme deficiency,
the immune system apparently treats the recombinant
human enzyme as a foreign protein. The extent of the
antibody response may depend on whether ARSB is
not produced at all, is misfolded and prematurely de-
graded, or finds its way to the lysosomes but lacks
function, all of which depends on the mutations in
the ARSB gene.
Here, we report on the genotypes and phenotypes of
12 Dutch patients with MPS VI, and on the correlation
between genotypes, antibody response, and therapeutic
effect of ERT.
Methods
Patients
Dutch patients with MPS VI are diagnosed, treated and
followed-up by the Center for Lysosomal and Metabolic
Diseases at Erasmus MC. Since 2007, twelve patients
were referred to our center. Their diagnosis was based
on a combination of clinical findings, arylsulfatase B de-
ficiency in fibroblasts, and the presence of a pathogenic
mutation in each of the two ARSB alleles. ERT treat-
ment for MPS VI consists of 1 mg/kg recombinant hu-
man arylsulfatase B (galsulfase, NaglazymeW, BioMarin
Corporation), administered by infusion once a week.ARSB activity
The ARSB activity in fibroblasts was spectrophoto-
metrically measured on the basis of the conversion of
p-nitrocatecholdisulfate to paranitrocatechol, as previously
described, and is expressed in nmol paranitrocatechol lib-
erated per mg cellular protein per hour [9].
DNA analysis and site-directed mutagenesis
DNA was isolated from leukocytes or skin fibroblasts
using routine procedures. After amplification, the
exons and flanking intron regions of the ARSB gene
were sequenced using an ABI 3730 DNA Analyser
under standard GLP conditions. NM_32373.2 was used
as reference sequence for the coding regions, whereby
the ‘A’ nucleotide of the ATG translation-initiation
codon at nucleotide position 560 constitutes +1 num-
bering of the cDNA sequence. The ATG-codon repre-
sents +1 for the amino acid numbering according to
the galsulfase preprotein sequence NP_000037.2. The
positions of intronic sequence variations were assigned
on the basis of the cDNA sequence and the genomic
contig sequence NC_000005.9, whereby the ‘A’ of the
ATG start codon is at genomic position 78073032. The
full length ARSB cDNA sequence cloned in expression
vector pcDNA3 (p.V358; p.S384) was used as template
for site-directed mutagenesis [10]. To introduce all mu-
tations except splice-site mutations and established
polymorphic sequence variations such as p.S384N into
the wild-type ARSB cDNA, we used the QuickChange
XL Site-Directed Mutagenesis Kit (Stratagene Life
Technologies Co., La Jolla, CA, USA) for site-directed
mutagenesis. In each case, the integrity of the resulting
mutant constructs was confirmed by full-length se-
quencing of the ARSB cDNA insert.
Two independent colonies of each mutation were used
to transfect COS-7 cells. The wild-type ARSB cDNA
construct in pcDNA3 served as positive control, and a
similar plasmid construct with the hexosaminidase-β
cDNA as negative control. COS-7 cells were seeded into
6-well plates and grown overnight in Dulbecco’s modi-
fied Eagle medium (DMEM) (Lonza, Verviers, Belgium)
supplemented with 10% fetal bovine serum (FBS), 50 U/ml
penicillin, and 50 μg/ml streptomycin. Cells at more than
90% confluence were transfected with 2.0 μg plasmid using
lipofectamine 2000 (InvitroGen). The cells were harvested
48 h and 72 hr later, and the ARSB activity was measured
in the cell homogenates using paranitrocatecholdisulfate
as substrate. The synthesis of ARSB was analysed by
SDS-PAGE and immunoblotting using a polyclonal rabbit
antiserum against recombinant human arylsulfatase B
(galsulfase, NaglazymeW). In this assay, different molecu-
lar mass species reflect the synthesis of ARSB as 66 kD
precursor, which is post-translationally modified to ma-
ture enzyme of 43 kD [11].
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Immuno-precipitation
Blood samples for antibody titer determination were drawn
just before the start of galsulfase infusions. Serum was pre-
pared and stored at −80°C. Starting with a 25-fold dilution,
two-fold serial dilutions were made in acetate buffer
pH 6.0 (0.5 M sodium acetate, 10 mM barium acetate and
0.02% sodium azide) containing bovine serum albumin
(BSA, Sigma) in a concentration of 0.2 mg/ml. A 10 μl so-
lution of a 250-fold dilution of galsulfase (total acti-
vity approximately 0.3 μmol/hr) in acetate buffer was
mixed with 10 μl diluted serum and 60 μl of a 1:6 sus-
pension of Protein A Sepharose CL-4B beads in PBS.
The mixture was incubated under continuous agitation
for 1 h at room temperature. The beads were then re-
moved by centrifugation (14,000 g), and the activity of
galsulfase in the supernatant was measured with
paranitrocatecholdisulfate.
Pharmacokinetic (PK) analysis
Blood was drawn before the start of galsulfase infusion,
and 1 h, 2 h and 2.5 h thereafter. It was collected again
15 min before the end of galsulfase infusion, at the end
of the infusion, and 15, 30, 60 and 120 min thereafter.
Plasma was prepared and stored at −80°C until use. To
measure the percentage of antibody-bound galsulfase we
used Sepharose beads, with and without Protein A
bound to it, for precipitation as described in the prece-
ding paragraph.
ELISA
ELISA was used as a third method to determine anti-
body formation in response to ERT with galsulfase. A
96-well plate (Nunc, F96 Maxisorp, Denmark) was
coated with 50 μL/well galsulfase in a concentration of
5 μg/mL diluted in phosphate-buffered saline (PBS,
pH 7.4), and incubated for 2 hours at room temperature
while shaking. Plates were blocked with 250 μL/well
BSA/PBS (1 gram BSA/100 ml PBS from Sigma A7030),
and incubated overnight at 4°C. After incubation, the
plates were rinsed six times at room temperature with
200 μL washing buffer (0.5 mL Tween-20 per liter PBS).
Plates were incubated with 50 μL of 5-fold serial dilutions
of patients’ sera for one hour while shaking. Samples were
diluted in dilution buffer (1 gram BSA and 50 μL Tween-
20 per 100 mL PBS) in dilutions that ranged from 50-fold
to 3,906,250-fold. A healthy person’s serum was used as a
negative control, and rabbit antiserum prepared against
galsulfase was used as a positive control. After washing,
50 μL conjugate was added to each well. For patients’ sera,
we used polyclonal anti-human-[IgG, IgA and IgM]-HRP
(Acris) in a 20,000-fold dilution. For polyclonal rabbit anti-
serum, we used anti-rabbit-IgG-HRP (Sigma) in a 10,000
fold dilution. After washing, 100 μL TetramethylbenzidineMicrowell Peroxidase substrate (Kirkegaard and Perry
Laboratories, Maryland) was added, and the plates were in-
cubated for 10 minutes. The colorimetric reaction was
stopped by adding 100 μL 1 M phosphoric acid (H3PO4).
Absorbance was measured at 450 nm using a spectropho-
tometer (Thermo Electron corporation, Vantaa, Finland).
The titer was determined as the maximal dilution at which
absorbance was at least twice the absorbance of the nega-
tive control.
Inhibition of galsulfase uptake
To assess the interference of antibodies with the uptake
of galsulfase by human fibroblasts we added 160 μl
plasma from patient 2, collected at peak-rate galsulfase
infusion, to 640 μl culture medium (Ham’s F10
supplemented with 3 mM Pipes) in a 6-well-tissue-culture
plate containing fibroblasts of this patient. In parallel, we
added to other wells galsulfase in an amount equivalent to
2400 nmol/h ARSB activity in combination with either
polyclonal rabbit anti-galsulfase antiserum or serum from
a healthy individual. Uptake of galsulfase by the cells was
measured 48 hours later.
Clinical assessments
To evaluate the effect of ERT, we selected three vari-
ables: joint mobility (shoulder flexion), urinary GAGs
and pulmonary function (Forced Vital Capacity, FVC).
All assessments were performed according to standard
protocol. The study protocol was approved by the
Medical Ethical Committee at Erasmus MC University
Medical Center.
Results
Patients
We describe 12 patients with mucopolysaccharidosis
type VI in 10 unrelated families (Table 1). Five of the
twelve patients had a rapidly progressive phenotype and
presented before the age of 5 years with cardiomyopathy,
dysmorphic facial features and/or severe joint limita-
tions. The remaining seven patients had a slowly pro-
gressive phenotype. The diagnosis of all twelve patients
was confirmed by the finding of ARSB deficiency in cul-
tured skin fibroblasts, elevated GAG levels in their
urines, and pathogenic mutations in both ARSB alleles.
GAG values appeared to correlate with disease status.
The pathogenic sequence variations comprised 7 mis-
sense mutations, 1 nonsense mutation and 1 mutation
in the splice-donor site of exon 6. Four of these nine
mutations were not previously reported. Eight of the
12 patients were the children of consanguineous mar-
riages (third degree or higher) and were homozygous
for the given mutations (Table 1).
Except for patient 12, all patients are currently receiving
ERT (galsulfase, NaglazymeW, 1 mg/kg weekly); three of
Table 1 ARSB genotypes and phenotypes of 12 MPS VI patients
Pt Age at start
of ERT
Age at diagnosis
(years)
Main presenting
symptom at
diagnosis (years)
GAG at start of ERT
(μg/mg creatinine)
ARSB activity
fibroblasts
(nmol/h*mg)
Allele 1
DNA^
Protein Allele 2
DNA^
Protein Progression Ethnicity
1. 2.1 1.8 cardiomyopathy 941.6 85.7 c.903C > G
c.1151G > A*
p.N301K
p.S384N*
c.903C > G
c.1151G > A*
p.N301K
p.S384N*
Rapid Turkish
2. 6.8 3.4 cardiomyopathy 1286.6 84.8 c.1142 + 2T > C c.1142 + 2T > C Rapid Pakistani
3. 2.9 2.8 cardiomyopathy 554.4 32.3 c.995T > G p.V332G c.995T > G p.V332G Rapid Marrocan
4. 2.3 1.9 macrocephalia 739.2 57.6 c.971G > T p.G324V c.971G > T p.G324V Rapid Guinean
5. 8.3 7.8 joint abnormalities
dysmorphic features
254.3 79.9 c.454C > T p.R152W c.454C > T p.R152W Slow Turkish
6.α 18.3 10.1 joint abnormalities 105.6 46.7 c.454C > T p.R152W c.454C > T p.R152W Slow Turkish
7. α 7.6 0.7 positive sibling 230.6 61.9 c.454C > T p.R152W c.454C > T p.R152W Slow Turkish
8. 10.6 10.2 joint abnormalities 192.7 50 c.629A > G p.Y210C c.937C > G p.P313A Slow Dutch
9. 5.9 5.1 joint abnormalities
dysmorphic features
206.8 38 c.629A > G p.Y210C c.979C > T p.R327X Slow Dutch
10. β 7.8 7.4 trigger fingers 213.8 40.7 c.629A > G p.Y210C c.979C > T p.R327X Slow Dutch
11. β 6.1 5.8 positive sibling 158.4 32.3 c.629A > G p.Y210C c.979C > T p.R327X Slow Dutch
12.# n.a. 2.8 joint abnormalities 712.8 57 c.710C > A p.A237D c.710C > A p.A237D Rapid Iranian
Pt patient; α, β siblings; GAG glycosaminoglycans; ARSB Arylsulfatase B; ARSB activity, normal range 379–980 nmol/mg/hr; ^NCBI Reference sequence: NM_000046; * S384N has previously been described as a
polymorphic change; novel mutations are marked in bold; #Pt 12 did not receive ERT in our hospital and is therefore only included in the genotype-phenotype section.
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had infusion-associated reactions (IAR); these consisted of
urticaria and general malaise.
Biosynthesis of ARSB
ARSB is synthesized as a polypeptide of 533 amino acids
that is co-translationally delivered into the lumen of the
endoplasmic reticulum (ER) [12]. The 39 amino acids
long N-terminal signal peptide is cleaved off, and the
protein is glycosylated and folded. It attains a relative
molecular mass of 66 kD, but is subsequently processed
to a lysosomal form of approximately 43 kD with a cen-
tral domain of 7 kD and a carboxyl-terminal domain of
8 kD [13].
To study the effect of the mutations in the ARSB gene,
we attempted to visualize the synthesis and post-
translation modification of ARSB in the patients’ fibro-
blasts by SDS-PAGE followed by Western blotting.
However, due to the low intensity of the ARSB signal
and the presence of ‘background’ staining, we failed to
obtain clear results.
As an alternative approach, we then used site-directed
mutagenesis to introduce the mutations in the wild-type
ARSB cDNA, and expressed these constructs transiently
in COS-7 cells to gain an impression of how the muta-
tions affected the biosynthesis of ARSB (Figure 1). None
of the 7 missense mutations led to total loss of ARSB
protein synthesis. The 66 kD precursor was detectable inFigure 1 Transient expression of wildtype and mutant ARSB
cDNA constructs. COS-7 cells were transfected with wildtype (wt)
and mutant cDNA constructs. ‘mock’ indicates that the cells were
transfected with a cDNA construct containing beta-hexosaminidase
cDNA. SDS-PAGE followed by immunoblotting was performed and
polyclonal rabbit anti-galsulfase serum was used to visualize ARSB.
Equal amounts of protein were loaded per lane. The figure at the
top shows the result of a representative experiment obtained at
72 hours after transfection. The figure at the bottom shows the
ARSB activity as percentage of wild type ARSB activity as measured
in cell homogenates at 48 hours after transfection.all cases, but its amount varied from very little (V332G),
to clearly less than normal (N301K), to near normal
(G324V, R152W, Y210C, P313A, and A237D). By con-
trast, introduction of the nonsense mutation R327X
led to total loss of ARSB production (Figure 1). Not-
ably, expression of none of the missense mutations led
to the formation of mature 43 kD ARSB protein,
which was in our system best visualized at 72 hours
after transfection (Figure 1 top, for ARSBwt), whereas
the highest ARSB activity was measured at 48 hrs after
transfection (Figure 1, bottom). At this time point the
activity of R152W was barely above the ARSB activity
in mock transfected cells, while all other mutants had
less activity.
Immune response to ERT
Within the first half year of ERT, all patients developed
antibodies against galsulfase with an ELISA titer of at
least 1:250 (range of 1:250 to 1:31,250) (Figure 2). After
approximately three years of therapy, patient 2, who was
homozygous for the splice-site mutation c.1142 + 2 T > C,
had the highest antibody titer (1:156,250). Patient 4 had
the second highest titer (1:31,250). Most patients had titers
ranging from 1:1,250 to maximally 1:6,250, which
remained fairly stable from one year after start of therapy
until the end of follow-up.
As an alternative method of estimating the height of the
antibody titer, we performed an immunoprecipitation assay
in which a given amount of galsulfase was precipitated
from solution by serial dilutions of the patient’s serum. In
this assay, only patient 2 had a measurable antibody titer
(shown for patient 2 in Figure 3). This figure shows that
the titer was highest after 26 weeks of therapy and then
gradually declined over 4.5 years of follow-up. The result
was somewhat unexpected, since the ELISA titer remained
more or less constant over the same period (Figure 2).
In addition to these two methods of determining the
antibody titer, we also collected blood samples at regu-
lar intervals during the 5 hours of enzyme infusion in
order to measure the capture of galsulfase by circulat-
ing antibodies. In patient 2 we performed this assay at
4.5 years after start of ERT, when her ELISA titer was
1:31,250; in patient 6, we performed it after 3.2 years of
ERT, when his titer was 1:6,250. Figure 4 shows two
curves for each of these patients. The curves with open
symbols represent the total ARSB activity that was
measured in the plasma, whereas the curves with closed
symbols represent the galsulfase activity remaining after
precipitation of antibody-bound galsulfase mediated by
Protein A Sepharose. Thus, in patient 2, approximately
50% of galsulfase was antibody-bound after 2.5 hours
(150 minutes) of infusion. The proportion of antibody-
bound enzyme slightly decreased during infusion, and
was 31% at the end of the infusion (300 minutes). In
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Figure 3 Antibody titer of patient 2 by immunoprecipitation.
A fixed amount of galsulfase was incubated with serially
diluted serum of patient 2. X-axis: 1/dilution factor (for exam-
ple, 0.02 represents a dilution factor of 50). The antibody-
bound galsulfase was precipitated using Protein A Sepharose
beads, and the activity remaining in the supernatant was
measured with paranitrocatecholdisulfate. The numbers at the
right side of the curves represent the ERT duration in weeks
(w) or years (y). The ELISA titers at these time points were
1:31,250 except at the 4y point (1:156,250). The open squares
show the precipitation of galsulfase by rabbit anti-galsulfase
serum; the open circles show the precipitation of a healthy
individual (normal serum).
Figure 2 ELISA titers of patients receiving ERT. The black lines represent the patients with rapid disease progression; the grey lines represent
the patients with a slower disease progression.
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approximately 15% throughout infusion.Uptake of galsulfase by fibroblasts
To investigate the adverse effect that antibody-binding can
have on the efficacy of ERT, we measured the uptake of
galsulfase by cultured ARSB deficient fibroblasts. To this
end we collected blood-plasma from patient 2 during infu-
sion and selected the sample with the highest galsulfase ac-
tivity. An aliquot of this sample was added to the cell
culture medium. To other wells we added galsulfase to-
gether with either rabbit anti-galsulfase antiserum (rabbit
serum) or serum from a healthy individual (normal serum).
After 48 hours, the galsulfase activity in the medium
had dropped to 50% using normal serum and to 63%
using the patient’s sample. Addition of rabbit serum
resulted in a 50% drop of galsulfase activity within the
first 15 minutes, but no further drop in activity was mea-
sured in the following 48 hours. At this time point, the
cells were harvested and the intracellular galsulfase activity
was measured. Uptake of galsulfase from the patient’s sam-
ple was 42% less than uptake of galsulfase combined with
normal serum. The presence of rabbit antiserum inhibited
the uptake of galsulfase almost completely (98%).
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Figure 4 Antibody binding of galsulfase during infusion. Blood-plasma samples were collected from patient 2 and patient 6 just before start
of galsulfase infusion (0 min) and at time points thereafter. The open symbols present the total galsulfase activity measured in the plasma; the
closed symbols present the amount of activity remaining after Protein-A-Sepharose-mediated immunoprecipitation of antibody-bound ARSB. The
difference between the curves represents the proportion of antibody-bound enzyme. The activity in the supernatant was measured with
paranitrocatecholdisulfate and is expressed in nmol/10 μl per hour.
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Since the study group was very small and heterogeneous,
we could not perform statistical analysis. Because analysis
was further restricted by the limited availability and vari-
ability of clinical parameters, we could only investigate the
overall correlation between immune response and clinical
outcome. To this end, we compared the effect of ERT in
two patients who had rather different immune responses:
patient 2, whose antibody titers ranged from 1:31,250 to
1:156,250; and patient 6, whose titer was more or less con-
stant at 1:6,250. Figure 5 shows the responses of both pa-
tients on FVC, shoulder flexion and GAG excretion. In
both patients GAG values decreased significantly. GAG
values remained slightly above the upper limit of normal in
patient 2 over a period of 4.5 years. In patient 6, whose
urinary GAG content had been lower at baseline than in
patient 2, it normalized within 2.5 years of ERT.
Patient 2 had restrictive pulmonary disease at baseline
(FVC −5.5 SD). During ERT, this improved from −4.8
SD −2.4 SD, though her respiratory capacity must also have
been improved by the mitral valve replacement she under-
went in the same period. In patient 6, FVC was −1.8 SD
at baseline and −1.2 SD at last assessment. At start of
therapy, both patients had severe joint restriction. In
patient 2, the degree of shoulder flexion (starting
from a 94 degrees restrictive shoulder flexion at base-
line) improved by 30%; in patient 6, it improved by
12% (starting from 130 degrees restriction; normally
175–180 degrees). While the hepatomegaly and the
splenomegaly both improved significantly under ERT
in patient 2, no comparison was possible with patient
6, in whom these signs had not been evident at base-
line. Neither could the effects of ERT on cardiac pa-
rameters be compared, as patient 2 received a mitral
graft at the age of 7 years. Also the mild aortic regur-
gitation in patient 6 did not improve during ERT.Discussion
Since many pathogenic sequence variations have been
identified in the ARSB gene, a genotype-phenotype
correlation is slowly emerging [14-19] – a picture to
which this description of our twelve patients and their
genotypes now contributes. Five of our patients
presented with rapidly progressive disease; progression
in the other seven was slower. In total, we identified 9
different pathogenic mutations, 4 of which had not
been published previously. Together they compose 8
different pathogenic genotypes. MPS VI is indeed very
heterogeneous [13].
Genotypes and phenotypes
Like others, we found that the level of residual ARSB ac-
tivity in cultured fibroblasts using rather non-specific
artificial substrates is a poor means of differentiating be-
tween patients with different clinical phenotypes. The
radiolabeled three-saccharide substrates perform better
[20,21]. By contrast, urinary GAG content seems to help
indicating the degree of disease severity [12,22]. In our
patient group too, a high urinary GAG content (mainly
dermatan sulphate) of 300 μgram/mg creatinine or
higher was associated with a severe phenotype.
With regard to our patients’ genotypes, 4 patients were
homozygous for missense mutations and one was homo-
zygous for a splice-site mutation. The advantage of
homozygous genotypes over compound heterozygous
genotypes is that the impact of the genotype does not
need to be gathered from the additive effects of the two
individual mutant alleles. Karageorgos et al. were able to
correlate the genotype, urinary GAG excretion and
phenotype of several patients with homozygous missense
mutations [19].
Three of our patients were homozygous for p.R152W.
The fact that they were the least severely affected patients
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Figure 5 Shoulder flexion, pulmonary function and
glycosaminoglycan excretion. During ERT, shoulder flexion
(degrees), pulmonary function (FVC) and urinary glycosaminoglycan
(GAG) excretion were measured in patient 2 (● ) and patient 6 (■).
Shoulder flexion: normal range 175–180. Pulmonary function (FVC) is
expressed as a Z-score of the predicted value. GAG excretion: the
dashed lines denote the normal value for age (115 μg/mg creatinine
for patient 2, and 55 μg/mg creatinine for patient 6).
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dicating that patients with this mutation are not
amongst the most severely affected. One publication
about a 38-year-old woman describes this mutation as
being associated primarily with a ‘cardiac phenotype’
[23]. While our three patients with this mutation do
not have prominent cardiac signs, the oldest –who iscurrently 21 years old– does have mild aortic regurgi-
tation. By contrast, four of the other missense muta-
tions that we identified (p.N301K, p.V332G, p.G324V,
and p.A237D) are severely pathogenic; this is suggested
by the rapidly progressive phenotypes of the homozy-
gotes in which they were found. Only p.G324V has
been described previously, but in a compound het-
erozygote, meaning that its effect was still obscure
[19]. Its great severity is indicated by the fact that our
patient who is homozygous for it had macrocephalia,
hepatosplenomegaly, severe joint deformities and eye
problems at a very young age (2y old). As patient 2,
who is homozygous for 1142 + 2 T > C, also had a rap-
idly progressive phenotype we conclude that this newly
discovered mutation must be severe too. Moreover,
this mutation affects the invariant splice donor se-
quence and is therefore expected to completely dis-
rupt splicing [24]. Homozygosity for c.1142 + 1G > T
in a patient with a very high GAG content in urine –
like our patient– also resulted in total loss of ARSB
protein [19]. Among the remaining patients, we iden-
tified four compound heterozygotes carrying the
common p.Y210C mutation in combination with ei-
ther p.P313A (patient 8) or p.R327X (patients 9, 10
and 11). p.Y210C is known to be associated with an
intermediate MPS VI phenotype, which was also the
case in our patients with this mutation [25]. Com-
pound heterozygosity for p.Y210C and p.P313A was
earlier described by Karakeorgos et al. in association
with a slowly progressive phenotype [19].
The effect of 8 mutations was investigated by site di-
rected mutagenesis and transient expression studies.
Introduction of the non-sense mutation p.R327X in the
wild type ARSB cDNA construct led to total absence of
ARSB protein. The seven missense mutations had vari-
able effects on the biosynthesis of ARSB; some resulted
in (much) less than the normal amount of 66 kD precur-
sor while others did not seem to have a dramatic effect
on the amount of 66 kD ARSB as judged from several
independent experiments. The low amount of 66 kD pre-
cursor in the respective cases might point to aberrantly
folded proteins that are partly degraded by endoplasmic
reticulum-associated degradation (ERAD) [12,26,27]. The
expression of none of the 7 missense mutations in COS-7
cells led to the formation of both the 66 kD precursor as
well as the 43 kD processed form of ARSB and none
resulted in clearly measurable ARSB activity. This out-
come agreed with the very low ARSB activity in fibroblasts
of the patients. The lack of 43 kD ARSB by expression of
p.Y210C was unexpected since Brooks et al. demonstrated
in a pulse-chase experiment that 67% of p.Y210C-
substituted ARSB is processed to mature 43 kD enzyme.
However, the apparent discrepancy can relate to the fact
that different methods and different antibodies were
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Antibody response to galsulfase
Within 26 weeks from the start of galsulfase infusions all
patients showed seroconversion, which is consistent with
observations during the clinical trials [4]. The ELISA ti-
ters differed between patients, varying during ERT from
relatively low in some patients (1,250) to relatively high
(1:156,250) in others.
Patient 2 consistently had the highest antibody titers
and was the only patient who experienced infusion asso-
ciated reactions (IARs). Notably, due to homozygosity for
c.1142 + 2 T > C, the patient is not expected to have any
level of endogenous ARSB expression, and is therefore
immunologically naive to ARSB. This might underlie the
strong immune response. Her high antibody titer as mea-
sured by ELISA was confirmed by immuno-precipitation.
While the ELISA titer remained constantly high after
26 weeks of treatment, the titer obtained by immuno-
precipiation declined. This would imply that the pool of
antibodies directed against immobilized galsulfase (ELISA)
remained constant while the pool of antibodies against na-
tive galsulfase decreased. The assay in which the pool of
antibody-bound galsulfase is measured during enzyme in-
fusion probably mimics the actual situation best; from it,
we inferred that approximately 50% of galsulfase adminis-
tered to patient 2 was captured by antibodies at the time
that she had an ELISA titer of 1:31,250. In patient 6, whose
ELISA titer was 1:6,250, the percentage of antibody-bound
galsulfase was much lower.
With regard to the effect of antibody binding, we dem-
onstrated for patient 2 that it can inhibit the uptake of
galsulfase by cultured fibroblasts. It is plausible that a
similar effect occurs in vivo and can limit the effect of
ERT. In such a case, the adverse effect of antibody for-
mation can possibly be overcome by higher dosing, un-
less higher dosing would lead to higher antibody titers
or severe infusion-associated reactions.
We have no clinical indications that antibody forma-
tion in MPS VI has a very strong impact on the effect of
ERT. Despite the much higher percentage of antibody-
bound galsulfase during infusion in patient 2 compared
to patient 6, both patients had similar increases in shoul-
der flexion, FVC and decrease in urinary GAG. It is
known from other lysosomal storage diseases that im-
mune response to ERT can reduce therapeutic outcome.
In Pompe disease, for instance, antibody formation has
been associated with loss of milestones and decreased
pulmonary function [8]. In MPS VI, however, clinical
changes in response to ERT are more subtle and the ad-
verse effect of antibodies may go unnoticed [5]. We have
investigated the effects of enzyme-replacement therapy
in this patient group in a separate paper [29].Conclusions
In summary, our characterisation of the MPS VI patients
currently receiving ERT in the Netherlands reflects con-
siderable genetic heterogeneity. The clinical phenotypes
and the defects we observed in the biosynthesis of ARSB
show that some of the mutations we identified –known
and novel alike– are clearly more severe than others. As
in other lysosomal storage diseases, the antibody re-
sponse to ERT can differ greatly between patients and
may to some extent relate to the genotype [30]. Al-
though antibody formation seems to have little impact
on clinical outcome, we have demonstrated that the
antibody concentration in the blood can reach a level at
which it potentially affects the efficacy of ERT by
inhibiting uptake of enzyme by the target tissues.
Consent
Written informed consent was obtained from the patient
for publication of this report and any accompanying
images.
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